BLAINJECTIONINJECTABLE
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
AMJEVITA (adalimumab-atto) by Amgen is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2016.
Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMJEVITA is an adalimumab biosimilar (monoclonal antibody) developed by Amgen that blocks tumor necrosis factor (TNF) to reduce inflammatory disease activity. It is indicated for TNF-mediated inflammatory conditions including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug works by binding TNF receptors and neutralizing TNF-α, a key driver of immune-mediated inflammation.
Peak
AMJEVITA is in peak commercial phase as a biosimilar with established market penetration; team focus is on maintaining share against growing biosimilar competition and optimizing managed care access.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMJEVITA offers stable exposure to peak-cycle biologic commercialization and biosimilar market dynamics, but career growth is limited by product maturity and high competitive saturation. Long-term advancement depends on successfully defending market share through managed care excellence, real-world evidence, and patient support innovation rather than clinical development.
Brand Manager
Worked on AMJEVITA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.